Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(14 sites)

France

CHU de Besançon, Besançon

CH William Morey, Chalon-sur-Saône

Hôpital Henri Mondor, Créteil

Centre Georges François Leclerc, Dijon

Hôpital Nord Franche-Comté, Montbéliard

CHU de Montpellier, Montpellier

CH de Mulhouse, Mulhouse

Institut de Cancérologie de l'Ouest, Nantes

Centre Hospitalier Paris St Joseph, Paris

Groupe Hospitalier Paris Salpetrière, Paris

Hôpital BEAUJON, Paris

Institut Mutualiste Montsouris, Paris

CHU de Poitiers, Poitiers

Hôpital Paul Brousse, Villejuif